Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy.

• DOI: 10.1200/jco.2025.43.5_suppl.122
• Publication Date: 2025-02-18T14:35:11Z
• Authors: Jonathan Trinh; Sandra Frimpong; Yue Zhan; Kaeli Samson; Laura A. Graeff-A...; Benjamin A. Teply
• Keywords: Baseline (sea)

122 Background: Androgen deprivation therapy (ADT) is essential for management of advanced prostate cancer, yet it carries risks including osteoporosis and fragility fractures. Antiresorptive recommended to reduce fractures patients at high risk. However, precisely which should undergo formal screening with dual-energy X-ray absorptiometry (DEXA) baseline has been relatively unexplored. This study aims describe these fracture risks, the utility DEXA based upon Fracture Risk Assessment Tool (FRAX) scores, impact specific risk factors in this population. Methods: We performed a retrospective cross-sectional our institution cancer treated ≥1 year ADT between 2011 2024. Patients were excluded if their FRAX scores incalculable or they received antiresorptive prior starting ADT. Ten-year hip combined major osteoporotic calculated using without femoral neck T-scores all who scans. A was defined as 10-year ≥3% ≥20%. Differences dichotomous groups assessed independent samples t-tests, Chi-square tests, Fisher’s exact tests. Results: identified 515 an average age 70.1 years BMI 29.5 kg/m 2 . Four hundred forty-eight (87%) leuprolide ADT, 70 (13.6%) on prednisone-containing regimen, 66 (12.8%) active smokers. Based clinical data initiation (without from DEXA), 201 (39.0%) had by FRAX. Among 183 did have scans, 85 (46.4%) met criteria osteopenia while 14 (7.7%) T-score. Additionally, 48 (26.2%) therapy. The meeting therapy, general, older (73.3 vs. 67.9 years) weighed less (87.8 kilograms 96.3 kilograms). Conclusions: In institutional experience, nearly half long term significant warranting further stratification mitigation strategies. inform systematic approaches select those that do—and do not—require bisphosphonate denosumab hormone sensitive setting.